This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
BHIVA. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee. Lancet 1997;349: 1086–92.
Bocket L, Ajana F, Senneville E, et al. Long terum HIV-1 viral load suppression. Comparative study of bitherapy and tritherapy. 37th ICAAC. Toronto, Canada, 1997:1-108.
Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349: 1413–21.
Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with Ritonavir: update. XI International Conference on AIDS, Vancouver, Canada, 1996:Mo. B. 411.
Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Updated recommendations of the International AIDS Society-USA. Journal of the American Medical Association 1997;277: 1962–1969.
Carr A, Emery S, Kelleher A, et al. CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13: 320–6.
CDC. Update: Trends in AIDS incidence, deaths, and prevalence-United States, 1996. MMWR 1997;46: 165–73.
Clumeck N. Clinical benefit of saquinavir (SQV) plus zalcitabine (ddC) plus zidovudine in untreated/minimally treated HIV-infected patients. 37th ICAAC. Toronto, Canada, 1997:LB-4.
Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374: 569–71.
D’Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med 1996;124: 1019–30.
D’Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med 1995;122: 401–8.
Davey RT, Jr., Chaitt DG, Reed GF, et al. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother 1996;40: 1657–64.
Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet. 1996;348: 283–91.
Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333: 1662–9.
Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11: FS113–FS116.
Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317: 185–91.
Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med 1990; 112: 727–37.
Gill MJ, Beall G, Beattie D, et al. Safety of Saquinavir soft gelatine capsule (SQV-SQC) in combination with other antiretroviral agents: multicenter study NV15182:24 weeks analysis. 37th ICAAC Toronto, Canada, 1997:I-90.
Gross PA, Barrett TL, Dellinger EP, et al. Purpose of Quality Standards for infectious diseases. Clinical Infectious Diseases 1994;18: 421.
Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337: 734–9.
Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med 1996;335: 1081–90.
Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337: 725–33.
Harris M, Rachlis A, Shillington A, et al. Long term suppression of HIV in plasma with a combination of two nucleosides and nevirapine. 37th ICAAC. Toronto, Canada, 1997:I-86.
Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997;126: 929–38.
Jacobson MA, Zegans M, Pavan PR, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997;349: 1443–5.
Kinloch-De Loes S, Hirschel BJ, Hoen B, et al. A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med 1995;333: 408–13.
Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Annals of Internal Medicine 1997;126: 946–54.
Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 Dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 1996;271: 1582–6.
Pollard R, Peterson D, Hardy D, et al. Antiviral effect and safety of stavudine (d4T) and didanosine (ddI) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blindtrial. Third Conference on Retroviruses and Opportunistic Infections. Washington, D.C., USA, 1996.
Raffi F, Reliquet V, Auger S, et al. A pilot tiral of antiviral activity and safety of didanosine-stavudine combination therapy in HIV-infected subjects: the quintet trial. 37th ICAAC. Toronto, Canada, 1997:I-123.
Saag M, Knowles M, Chang Y, et al. Durable effect of viracept (nelfinavir mesylate, nrV) in triple combination therapy, 37th ICAAC. Toronto, Canada, 1997:I-101.
Schmit JC, Cogniaux J, Hermans P, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996;174: 962–8.
Shafer RW, Winters MA, Iversen AK, et al. Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors, Antimicrob Agents Chemother 1996;40: 2887–90.
Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expressin in patients infected with human immunodeficiency virus type 1. New England Journal of Medicine 1996;334: 1222–30.
Staszewski S, Miller V, Rehmet S, et al. Virological and immunological analysis of a triple combination pilot sutyd with loviride, lamivudine and zidovudine. AIDS 1996;10: F1–7.
Author information
Authors and Affiliations
Consortia
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
HIV-Arbeitskreis Südwest., Deutsche AIDS-Hilfe e.V.. (1998). Anhang. In: HIV und AIDS. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-07794-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-662-07794-8_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-07795-5
Online ISBN: 978-3-662-07794-8
eBook Packages: Springer Book Archive